Moderna (NASDAQ: MRNA) has dosed the first participants in a Phase 1 clinical trial of mRNA-1469, an investigational mRNA vaccine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE